SCHEMBL8360744

SCHEMBL8360744

COc1ccc(N2CCN(C)CC2)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.62
DRD3 P35462 3/20 0.62
MAPT P10636 2/20 0.57
MAPK1 P28482 1/20 0.57
HTT P42858 1/20 0.57
KDM4E B2RXH2 2/20 0.50
HTR1A P08908 2/20 0.50
TSHR P16473 2/20 0.49
STK33 Q9BYT3 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
LMNA P02545 1/20 0.47
DRD1 P21728 1/20 0.47
DRD5 P21918 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17145033 0.94 DRD2 (0.55) DRD2DRD3MAPTMAPK1HTT
SCHEMBL5566877 0.86 ALDH1A1 (0.61) MAPTHTTKDM4EHTR1ATSHR
SCHEMBL13030868 0.84 ALDH1A1 (0.59) MAPTMAPK1HTTKDM4EHTR1A
SCHEMBL21659769 0.84 HTR1A (0.53) DRD2DRD3MAPTHTR1ASMN1; SMN2
SCHEMBL14922712 0.83 HTR3E (0.69) DRD2DRD3MAPTMAPK1HTT
SCHEMBL12082468 0.83 DRD2 (0.62) DRD2DRD3MAPTHTTHTR1A
SCHEMBL12551006 0.82 TSHR (0.49) DRD2DRD3MAPTMAPK1HTT
SCHEMBL13033072 0.82 KMT2A (0.47) DRD2DRD3MAPTMAPK1HTT
SCHEMBL13073690 0.82 MAPK1 (0.56) DRD2DRD3MAPTMAPK1KDM4E
SCHEMBL4395362 0.82 HTR1A (0.56) DRD2DRD3KDM4EHTR1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE44205-E1 Adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases CTSK, CTSS, CTSZ DRD2 4870/4885DRD3 4862/4885MAPT 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.